FDA cleared the cobas eplex respiratory pathogen panel 3 from GenMark Diagnostics, Inc. on Oct 30, 2026 under K262938, a traditional 510(k). The device falls under product code QOF, Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents, regulated at 21 CFR 866.3981 as a Class 2 device. The review panel was Microbiology.

FDA logged the submission as received on Aug 21, 2026. The decision came 70 days later, inside the 90 FDA-day goal for a 510(k).

This is the only decision on file for GenMark Diagnostics, Inc. in the last 12 months of the tracker.